Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance

Balko, Justin M, Cook, Rebecca S, Vaught, David B, Kuba, María G, Miller, Todd W, Bhola, Neil E, Sanders, Melinda E, Granja-Ingram, Nara M +10 more·2012·Nature Medicine

DOI 10.1038/nm.2795

Cited by (264)

Items 101–200 of 264

Genome-wide characterization of human minisatellite VNTRs: population-specific alleles and gene expression differences
Marzieh Eslami Rasekh, Yozen A. Hernandez, Samantha D. Drinan, Juan I. Fuxman Bass, Gary Benson · 2021 · Nucleic Acids Research
Residual Prostate Cancer Cells after Docetaxel Therapy Increase the Tumorigenic Potential via Constitutive Signaling of CXCR4, ERK1/2 and c-Myc
Koji Hatano, Souhei Yamaguchi, Keisuke Nimura, Kouki Murakami, Akira Nagahara, Kazutoshi Fujita, Motohide Uemura, Yasutomo Nakai, Mutsumi Tsuchiya, Masashi Nakayama et al. · 2013 · Molecular Cancer Research
Targeting the XIAP/caspase-7 complex selectively kills caspase-3–deficient malignancies
Yuan‐Feng Lin, Tsung‐Ching Lai, Chih‐Kang Chang, Chi‐Long Chen, Ming-Shyan Huang, Chih‐Jen Yang, Hon-Ge Liu, Jhih-Jhong Dong, Yi-An Chou, Kuo-Hsun Teng et al. · 2013 · Journal of Clinical Investigation
Changing the expression vector of multidrug resistance genes is related to neoadjuvant chemotherapy response
Николай Васильевич Литвяков, Н. В. Чердынцева, Matvey Mikhailovich Tsyganov, Evgeny V. Denisov, Е. Yu. Garbukov, М К Мерзлякова, В. В. Волкоморов, Sergey Vladimirovich Vtorushin, Marina V. Zavyalova, Elena M. Slonimskaya et al. · 2012 · Cancer Chemotherapy and Pharmacology
A novel triazole, NMK-T-057, induces autophagic cell death in breast cancer cells by inhibiting γ-secretase–mediated activation of Notch signaling
Amlan Kumar Das, Maruthi Kumar Narayanam, Santanu Paul, Pritha Mukhnerjee, Suvranil Ghosh, Debabrata Ghosh Dastidar, Subhendu Chakrabarty, Arnab Ganguli, Biswarup Basu, Mahadeb Pal et al. · 2019 · Journal of Biological Chemistry
A Transposon-based Analysis Reveals RASA1 Is Involved in Triple-Negative Breast Cancer
Cristian Suárez-Cabrera, Rita M. Quintana, Ana Bravo, M. Casanova, Angustias Page, Josefa P. Alameda, Jesús María Paramio, Alicia Maroto, Javier Salamanca, Adam J. Dupuy et al. · 2017 · Cancer Research
Strategic Developments & Future Perspective on Gene Therapy for Breast Cancer: Role of mTOR and Brk/ PTK6 as Molecular Targets
Roja Sahu, Shakti Prasad Pattanayak · 2020 · Current Gene Therapy
Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency
Hae Hyun Jung, Soo Hyun Lee, Ji‐Yeon Kim, Jin Seok Ahn, Yeon Hee Park, Young‐Hyuck Im · 2016 · Scientific Reports
Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation
Giacomo Pelizzari, Lorenzo Gerratana, Debora Basile, Valentina Fanotto, Michele Bartoletti, Alessia Liguori, Caterina Fontanella, Simon Spazzapan, Fabio Puglisi · 2018 · Cancer Treatment Reviews
Single-Cell RNA Sequencing Reveals the Migration of Osteoclasts in Giant Cell Tumor of Bone
Wenyu Feng, Mingwei He, Xiaohong Jiang, Huijiang Liu, Tianyu Xie, Zhaojie Qin, Qian Huang, Shijie Liao, Chengsen Lin, Juliang He et al. · 2021 · Frontiers in Oncology
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma
Avinash Gupta, Christopher Towers, F. Willenbrock, R. Brant, D. Hodgson, A. Sharpe, Philip Smith, A. Cutts, A. Schuh, R. Asher et al. · 2019 · British Journal of Cancer
Downregulation of dual‐specificity phosphatase 4 enhances cell proliferation and invasiveness in colorectal carcinomas
Michihiro Ichimanda, Naoki Hijiya, Yoshiyuki Tsukamoto, Tomohisa Uchida, Chisato Nakada, Tomonori Akagi, Tsuyoshi Etoh, Hidekatsu Iha, Masafumi Inomata, Mutsuhiro Takekawa et al. · 2017 · Cancer Science
A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics
Jelmar Quist, Hasan Mirza, Maggie C.U. Cheang, Melinda L. Telli, Joyce O’Shaughnessy, Christopher J. Lord, Andrew N.J. Tutt, Anita E. Grigoriadis · 2018 · Molecular Cancer Therapeutics
GFAP alternative splicing regulates glioma cell–ECM interaction in a DUSP4‐dependent manner
Emma J. van Bodegraven, Jessy V. van Asperen, Jacqueline A. Sluijs, Coen Van Deursen, Miriam E. van Strien, Oscar M. J. A. Stassen, Pierre A. J. T. Robe, Elly M. Hol · 2019 · The FASEB Journal
Predicting the clinical outcome of oral potentially malignant disorders using transcriptomic-based molecular pathology
Hans Prakash Sathasivam, Ralf Kist, Philip Sloan, Peter James Thomson, Michael Nugent, John J. Alexander, Syed Aleem Haider, Max Robinson · 2021 · British Journal of Cancer
Methylation of dual-specificity phosphatase 4 controls cell differentiation
Hairui Su, Ming Zuo Jiang, Chamara Senevirathne, Srinivas Aluri, Tuo Zhang, Han Guo, Juliana M. Xavier-Ferrucio, Shuiling Jin, Ngoc Tung Tran, Szumam Liu et al. · 2021 · Cell Reports
Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease
Dawid Mehlich, Anna A. Marusiak · 2022 · Cancer Letters
Neuropeptide Y1 receptor inhibits cell growth through inactivating mitogen-activated protein kinase signal pathway in human hepatocellular carcinoma
Xiufang Lv, Fengbo Zhao, Xisong Huo, Weidong Tang, Baoying Hu, Xiu Gong, Juan Yang, Qiujin Shen, Wenxin Qin · 2016 · Medical Oncology
DUSP4 promotes esophageal squamous cell carcinoma progression by dephosphorylating HSP90β
Liting Zhou, Ning Yao, Lu Yang, Kangdong Liu, Yan Qiao, Chuntian Huang, Ruijuan Du, Yiu To Yeung, Wenting Liu, Dan Cheng et al. · 2023 · Cell Reports
Research advances and new challenges in overcoming triple-negative breast cancer
Yu Zong, Mark Daniel Pegram · 2021 · Cancer Drug Resistance
Post-diagnostic statin use and breast cancer-specific mortality: a population-based cohort study
Oliver William Scott, Sandar Tin Tin, Sixten Harborg, Marion J J Kuper-Hommel, Ross A Lawrenson, Mark Elwood · 2023 · Breast Cancer Research and Treatment
Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors
María del Rosario Chica-Parrado, Ana Godoy-Ortíz, Begoña Jiménez, Nuria Ribelles, Isabel Barragán, Emilio Alba · 2020 · Cancers
SIK2 attenuates proliferation and survival of breast cancer cells with simultaneous perturbation of MAPK and PI3K/Akt pathways
Neslihan Zohrap, Özge Saatci, Burçak Özeş, İpek Çoban, Hasan Murat Atay, Esra Battaloğlu, Özgür Şahin, Kuyaş Buğra · 2018 · Oncotarget
Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling
Zhangqian Chen, Lin Zhang, Limin Xia, Yangsheng Jin, Qing Hua Wu, Hao Guo, Xin Chun Shang, Jianhua Dou, Kaichun Wu, Yongzhan Nie et al. · 2014 · Cancer Letters
Regional methylome profiling reveals dynamic epigenetic heterogeneity and convergent hypomethylation of stem cell quiescence-associated genes in breast cancer following neoadjuvant chemotherapy
Yumei Luo, Juan Huang, Yi Tang, Xitu Luo, Lingxia Ge, Xiujie Sheng, Xiaofang Sun, Yaoyong Chen, Detu Zhu · 2019 · Cell & Bioscience
Defining a Role and Predicting Benefit From Platinum-Based Therapy in Breast Cancer: An Evolving Story
Joseph A. Sparano · 2014 · Journal of Clinical Oncology
DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype
Veerle de Vriendt, Wendy De Roock, Antonio Fabio Di Narzo, Sun Tian, Bart Biesmans, Bart Jacobs, Eva Budínská, Xavier Sagaert, Simona Rossi, Giovanni D’Ario et al. · 2013 · Biomarkers
Dual specificity phosphatase 4 gene expression in association with triple-negative breast cancer outcome
Michelle L. Baglia, Qiuyin Cai, Ying Zheng, Jie Wu, Timothy Su, Fei Ye, Ping‐Ping Bao, Hui Cai, Zhiguo Zhao, Justin Micah Balko et al. · 2014 · Breast Cancer Research and Treatment
Recent Advances of Nanotechnology in the Diagnosis and Therapy of Triple- Negative Breast Cancer (TNBC)
Abhishek Kanugo, Rupesh Kumar Gautam, Mohammad Amjad Kamal · 2021 · Current Pharmaceutical Biotechnology
Basal–epithelial subpopulations underlie and predict chemotherapy resistance in triple-negative breast cancer
Mohammed Inayatullah, Arun Mahesh, Arran Turnbull, J. Michael Dixon, Rachael Natrajan, Vijay Kumar Tiwari · 2024 · EMBO Molecular Medicine
Loco-regional Control After Neo-adjuvant Chemotherapy and Conservative Treatment for Locally Advanced Breast Cancer Patients
Antonin Lévy, Isabelle Borget, Manel Bahri, Mónica Arnedos, Eleonor Rivin del Campo, Philippe R. Vielh, Corinne Balleyguier, Françoise Rimareix, C. Bourgier · 2014 · The Breast Journal
Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface
Erik Russell Nelson, Shenduo Li, Margaret N. Kennedy, Sturgis Payne, Kelly Kilibarda, Jeffrey Groth, Michelle L. Bowie, Edgardo R. Parrilla Castellar, Gustaaf de Ridder, Paul Kelly Marcom et al. · 2016 · Oncotarget
Enhanced O-linked Glcnacylation in Crohn's disease promotes intestinal inflammation
Qian-Hui Sun, Yi-Shu Wang, Guolong Liu, Hong-Lan Zhou, Yong‐Ping Jian, Ming-Di Liu, Dan Zhang, Qiang Ding, Rui–Xun Zhao, Jian-Feng Chen et al. · 2020 · EBioMedicine
Subpathway Analysis of Transcriptome Profiles Reveals New Molecular Mechanisms of Acquired Chemotherapy Resistance in Breast Cancer
Yang Huo, Shuai Shao, Enze Liu, Jin Li, Zhen Tian, Xue Wu, Shijun Zhang, Daniel G. Stover, Huanmei Wu, Lijun Cheng et al. · 2022 · Cancers
Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer
Maki Tanioka, Kazuko Sakai, Tamotsu Sudo, T. Sakuma, Kazuyoshi Kajimoto, Koichi Hirokaga, Shintaro Takao, Shunichi Negoro, Hironobu Minami, Kazuhiko Nakagawa et al. · 2014 · Breast Cancer Research and Treatment
miR-1226-3p Promotes Sorafenib Sensitivity of Hepatocellular Carcinoma via Downregulation of DUSP4 Expression
Xianqing Chen, Wenliang Tan, Wenxin Li, Wenda Li, Sicong Zhu, Jinyi Zhong, Changzhen Shang, Yajin Chen · 2019 · Journal of Cancer
Liver kinase B1 regulates the centrosome via PLK1
Kaitlin D. Werle, J. Chen, H-G Xu, R-X Zhao, Q He, C Lu, Rutao Cui, Jiyong Liang, Y-L Li, Z-X Xu · 2014 · Cell Death and Disease
Adding Adjuvant Systemic Treatment after Neoadjuvant Therapy in Breast Cancer: Review of the Data
Shetal Arvind Patel, Angela M. DeMichele · 2017 · Current Oncology Reports
Supplementary Materials and Methods
Floris H. Groenendijk, Wilbert T. Zwart, Arno N. Floore, Stephanie Akbari, René Bernards · 2013
Phosphatases and solid tumors: focus on glioblastoma initiation, progression and recurrences
Matthias Dedobbeleer, Estelle Willems, Stephen D. Freeman, Arnaud Lombard, Nicolas Goffart, Bernard Rogister · 2017 · Biochemical Journal
A cellular automata model of chemotherapy effects on tumour growth: targeting cancer and immune cells
Fateme Pourhasanzade, S. H. Sabzpoushan · 2019 · Mathematical and Computer Modelling of Dynamical Systems
Chromosome 12p Amplification in Triple-Negative/ BRCA1- Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity
Jorge Gomez Miragaya, Ander Díaz‐Navarro, Raúl Tonda, Sergi Beltrán, Luís Palomero, Marta Palafox, Lacey Elizabeth Dobrolecki, Chen Lu Huang, Suhas V. Vasaikar, Bing Zhang et al. · 2019 · Cancer Research
Identification of miRNA Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response
Ai‐Yan Xing, Bin Wang, Yu-Hong Li, Xu Chen, Ya‐Wen Wang, Haiting Liu, Peng Gao · 2021 · Pathology & Oncology Research
The therapeutic significance of the novel photodynamic material TPE-IQ-2O in tumors
Liyu Wang, Yu Liu, Hengchang Liu, He Tian, Yalong Wang, Guochao Zhang, Yuanyuan Lei, Liyan Xue, Bo Jian Zheng, Tao T. Fan et al. · 2020 · Aging
Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer
Won‐Ji Ryu, Joohyuk Sohn · 2021 · Pharmaceuticals
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
Alberto J. Arribas, Sara Napoli, Luciano Cascione, Laura Barnabei, Giulio Sartori, Eleonora Cannas, Eugenio Gaudio, Chiara Tarantelli, Afua A. Mensah, Filippo Spriano et al. · 2023 · Molecular Cancer Therapeutics
Targeting kinases that regulate programmed cell death: a new therapeutic strategy for breast cancer
Yun Chul Hong, Jun He, Dan Deng, Qinyue Liu, Xuyu Zu, Yingying Shen · 2025 · Journal of Translational Medicine
DUSP4/MKP2 overexpression is associated with BRAFV600E mutation and aggressive behavior of papillary thyroid cancer
Yu Wang, Ben Ma, Rong‐Liang Shi, Shuwen Yang, Li Zhou, Ning Qu, Tian Liao, Yulong Wang, Qinghai Ji · 2016 · OncoTargets and Therapy
Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8+ T-cells infiltration in triple-negative breast cancer
Murugan Kalimutho, Debottam Sinha, Deepak Mittal, Sriganesh Srihari, Devathri M. Nanayakkara, Shagufta Shafique, Prahlad V. Raninga, Purba Nag, Kate Parsons, Kum Kum Khanna · 2019 · Journal of Experimental & Clinical Cancer Research
Lymphoma Microenvironment in DLBCL and PTCL-NOS: the key to uncovering heterogeneity and the potential for stratification
Kohta Miyawaki, Takeshi Sugio · 2022 · Journal of the Japan Society of the Reticuloendothelial System
Gene heterogeneity in metastasis of colorectal cancer to the lung
Jiayun Hou, Yong Zhang, Zhitu Zhu · 2016 · Seminars in Cell and Developmental Biology
MIDAS: Mining differentially activated subpaths of KEGG pathways from multi-class RNA-seq data
Sangseon Lee, Youngjun Park, Sun Kim · 2017 · Methods
Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancers
Ramón González Manzano, E. Martinez-Navarro, Jerónimo Forteza, Antonio Brugarolas · 2014 · International Journal of Oncology
Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+ Early Stage Breast Cancer
Rami Sesha Vanguri, Kathleen M. Fenn, Matthew Kearney, Qi Wang, Hua Guo, Douglas Kanter Marks, Christine Chin, Claire F. Alcus, Julia B Thompson, Cheng‐Shiun Leu et al. · 2022 · Clinical Breast Cancer
Digital Quantification of Gene Expression in Sequential Breast Cancer Biopsies Reveals Activation of an Immune Response
Rinath M. Jeselsohn, Lillian L. Werner, Meredith M. Regan, Aquila Fatima, Lauren Gilmore, Laura C. Collins, Andrew H. Beck, Shannon Terrell Bailey, Housheng Hansen He, Gilles Buchwalter et al. · 2013 · PLoS ONE
COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy
Constantin Pixberg, Marc Zapatka, Mario Hlevnjak, S. Benedetto, Jan Philip Suppelna, Joerg Heil, Katharina Smetanay, Laura L. Michel, Carlo Fremd, V. Körber et al. · 2022 · ESMO Open
MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression
Sven Rottenberg, Jos Jonkers · 2012 · Breast Cancer Research
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer
Vishnu Prasath, H. Boutrid, Robert Wesolowski, Mahmoud Abdel‐Rasoul, Cynthia Dawn Timmers, Maryam B. Lustberg, Rachel M. Layman, Erin Renee Macrae, Ewa Mrózek, Charles L. Shapiro et al. · 2024 · Breast Cancer Research and Treatment
DUSP4 directly deubiquitinates and stabilizes Smad4 protein, promoting proliferation and metastasis of colorectal cancer cells
Weifeng Xu, Beibei Chen, Dianshan Ke, Xiaobing Chen · 2020 · Aging
Functional analysis of MKP-1 and MKP-2 in breast cancer tamoxifen sensitivity
Kelly K. Haagenson, Jessica Wei Zhang, Zhengfan Xu, Malathy P.V. Shekhar, Gen Sheng Wu · 2014 · Oncotarget
Tumor necrosis factor-α-mediated suppression of dual-specificity phosphatase 4: crosstalk between NFκB and MAPK regulates endothelial cell survival
Derrick D. Kao, Scott R. Oldebeken, Anjali Rai, Edith Lubos, Jane A. Leopold, Joseph Loscalzo, Diane E. Handy · 2013 · Molecular and Cellular Biochemistry
Precision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancer—A Review of Molecular Characterisation, Therapeutic Targets and Future Trends
Karen Pinilla, Lynsey M Drewett, Rebecca Lucey, Jean Abraham · 2022 · Frontiers in Oncology
ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma
Katherine E. Hutchinson, Douglas Buckner Johnson, Adam S. Johnson, Violeta M. Sanchez, Maria Gabriela Kuba, Lu Wang, Xi Chen, Mark C. Kelley, Qingguo Wang, Zhongming Zhao et al. · 2015 · Oncotarget
Dual-Specificity Protein Phosphatases Targeting Extracellular Signal-Regulated Kinases: Friends or Foes in the Biology of Cancer?
Alessandro Tubita, Dimitri Papini, Ignazia Tusa, Elisabetta Rovida · 2025 · International Journal of Molecular Sciences
Low-GPX4 drives a sustained drug-tolerant persister state in TNBC by a targetable adaptive FSP1 upregulation
Nazia Chaudhary, Dibita Mandal, Bhagya Shree Choudhary, Sushmita Patra, Darshan Jain, Pritam Poonia, Shagufa Shaikh, Siddhi Tekalkar, Shivani Malvankar, Anusha Shivashankar et al. · 2025 · Redox Biology
DUSP4 Silencing Enhances the Sensitivity of Breast Cancer Cells to Doxorubicin through the Activation of the JNK/c-Jun Signalling Pathway
Mashael S. Al-Mutairi, Hany Onsy Habashy · 2022 · Molecules
CREB1-BCL2 drives mitochondrial resilience in RAS GAP-dependent breast cancer chemoresistance
Ki-Fong Man, Omeed Darweesh, Jinghui Hong, Alexandra Thompson, Charlotte O’Connor, Chiara Bonaldo, Mark N. Melkonyan, Mo Sun, Rajnikant Patel, Leif William Ellisen et al. · 2025 · Oncogene
KDM4C inhibition blocks tumor growth in basal breast cancer by promoting cathepsin L-mediated histone H3 cleavage
Zheqi Li, Guillermo Peluffo, Laura E. Stevens, Xintao Qiu, Marco Seehawer, Amatullah Tawawalla, Xiao-Yun Huang, Shawn B. Egri, Shaunak Raval, Maeve McFadden et al. · 2025 · Nature Genetics
Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies
Peter Edward Hall, Peter Schmid · 2022 · Breast Cancer Research and Treatment
MicroRNA‐Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer
Sriganesh B. Sharma, John Michael Ruppert · 2015 · Drug Development Research
New Developments and Future Directions in Systemic Therapy
Amna Sheri, Stephen R.D. Johnston · 2012 · Clinical Oncology
Circulating Proteins Associated with Response and Resistance to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
María del Pilar Chantada‐Vázquez, Mercedes Conde‐Amboage, L. Graña-López, Sergio Vázquez‐Estévez, Susana B. Bravo, Cristina Núñez · 2022 · Cancers
Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancer
Ann Hanna, Mellissa J. Nixon, Monica Valeria Estrada, Violeta M. Sanchez, Quanhu Sheng, Susan R. Opalenik, Abigail L. Toren, Joshua A. Bauer, Philip Owens, Frank M. Mason et al. · 2022 · Breast Cancer Research
Proteolysis Targeting Chimera (PROTAC) as a promising novel therapeutic modality for the treatment of triple‐negative breast cancer (TNBC)
Gaidaa M. Dogheim, Mohamed T. Amralla · 2023 · Drug Development Research
Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumors
Xiaojia Tang, Kevin J. Thompson, Krishna R. Kalari, Jason P. Sinnwell, Vera Jean Suman, Peter T. Vedell, Sarah A. McLaughlin, DW Northfelt, Alvaro Moreno Aspitia, Richard J. Gray et al. · 2023 · Breast Cancer Research
Shifting the Paradigm: The Transformative Role of Neoadjuvant Therapy in Early Breast Cancer
Nader Hirmas, Johannes Holtschmidt, Sibylle Loibl · 2024 · Cancers
FRET biosensor-based kinase inhibitor screen for ERK and AKT activity reveals differential kinase dependencies for proliferation in TNBC cells
Jichao He, Steven Wink, Hans de Bont, Sylvia E. Le Dévédec, Ying-Hui Zhang, Bob van de Water · 2019 · Biochemical Pharmacology
Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer in Sub-Saharan Africa: A Retrospective Analysis of Recurrence and Survival in Women Treated for Breast Cancer at the Korle Bu Teaching Hospital in Ghana
Hannah Ayettey Anie, Joel Yarney, Olutobi Adekunle Sanuade, Shivanshu Awasthi, Tom Akuetteh Ndanu, Akash D. Parekh, Charles Akoto Aidoo, Mary Ann Dadzie, Verna D.N.K. Vanderpuye, Kosj Yamoah · 2021 · JCO Global Oncology
Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype
Marina Konstantinovna Ibragimova, Matvey Mikhailovich Tsyganov, Николай Васильевич Литвяков · 2021 · Cancers
Current therapeutics and treatment options in TNBC
Manzoor Ahmad Mir, Shariqa Aisha, Umar Mehraj · 2022 · Elsevier eBooks
PKM splice-switching ASOs induce upregulation of dual-specificity phosphatases and dephosphorylation of ERK1/2 in hepatocellular carcinoma
Dillon M. Voss, Alexander J. Kral, GeunYoung Sim, Raditya Utama, Kuan‐Ting Lin, Chris Cizmeciyan, Balázs Schäfer, Patrick J. Cunniff, Christopher R. Vakoc, Marvin H. Caruthers et al. · 2025 · Journal of Biological Chemistry
Risk factors of locoregional relapse in locally advanced breast cancer treated with neoadjuvant chemotherapy following mastectomy and radiotherapy
Liang Huang, Sheng Chen, Wentao Yang, Zhi‐Ming Shao · 2016 · Oncotarget
Aberrant expression of DUSP4 is a specific phenomenon in betel quid-related oral cancer
Bhoj Raj Adhikari, Koki Yoshida, Durga Paudel, Tetsuro Morikawa, Osamu Uehara, Jun Sato, Malsantha Muthumala, Prasad Amaratunga, Toshiya Arakawa, Itsuo Chiba et al. · 2020 · Medical Molecular Morphology
DUSP4 inhibited tumor cell proliferation by downregulating glycolysis via p-ERK/p-PGK1 signaling in ovarian cancer
Ying Xiong, Xiaoqian Zhang, Weiwei Xie, Yujia Yin, Yujing Qian, Xiang Ying, Xiaocui Zheng, Xipeng Wang · 2025 · Cancer Cell International
Low DUSP4 Expression Is Associated With Aggressive Phenotypes and Poor Prognosis in Gastric Cancer
Seongsik Bang, Seungyun Jee, Hyunsung Kim, KISEOK JANG, Hosub Park, Jae Kyung Myung, Dongho Choi, Su‐Jin Shin, Seung Sam Paik · 2021 · In Vivo
DUSP4 enhances therapeutic sensitivity in HER2-positive breast cancer by inhibiting the G6PD pathway and ROS metabolism by interacting with ALDOB
Xuliren Wang, Weiru Chi, Yuwei Ma, Qi Zhang, Jingyan Xue, Zhi‐Ming Shao, Bingqiu Xiu, Jiong Wu, Yayun Chi · 2024 · Translational Oncology
Cancer stem cell phosphatases
Majid Momeny, Tiina Arsiola, Jukka K. Westermarck · 2021 · Biochemical Journal
Silencing circFTO inhibits malignant phenotype through modulating DUSP4 expression in clear cell renal cell carcinoma
Chen Yang, Yiwen Zang, Siqi Wu, Quan Zhou, Yuxi Ou, Qiang Ding, Hao Wang, Zuquan Xiong · 2022 · Cell Death Discovery
Immuno-oncologic signature of malignant transformation in oral squamous cell carcinoma
Manar Elnaggar, Risa Chaisuparat, Ioana Ghita, Søren Møller Bentzen, Donita Dyalram, Robert Andrew Ord, Joshua Eli Lubek, Rania H. Younis · 2023 · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology
682: Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas
J. Li, Serena Bonifati, Georgi Hristov, T. Marttila, Jean Rommelaere, Antonio Marchini · 2014 · European Journal of Cancer
Dual-Specificity Phosphatase 11 Is a Prognostic Biomarker of Intrahepatic Cholangiocarcinoma
Xu Lin, Peng Wang, Wei Zhang, Weiran Li, Tao Liu, Xu Che · 2021 · Frontiers in Oncology
Short-Term Environmental Conditioning Enhances Tumorigenic Potential of Triple-Negative Breast Cancer Cells
Samantha S. Eckley, Johanna M. Buschhaus, Brock A. Humphries, Tanner H. Robison, Kathryn E. Luker, Gary D. Luker · 2019 · Tomography
Challenges in triple negative breast cancer treatment and therapeutic potential of the mitogen activated protein kinase pathway
Prettisha K. Nand, David R. Croucher, Levon Michael Khachigian · 2026 · Cancer Letters
Patterns of Dual-Specific Phosphatase 4 mRNA Expression Before and after Neoadjuvant Chemotherapy in Breast Cancer
Prihantono Prihantono, Andi Nilawati Usman, Christian Binekada, Mochammad Hatta, Andi Asadul Islam · 2019 · Asian Pacific Journal of Cancer Prevention
Loss of DUSP4 Expression as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma
Seongsik Bang, Seungyun Jee, Hwangkyu Son, Young Chan Wi, Hyunsung Kim, Hosub Park, Jae Kyung Myung, Su‐Jin Shin, Seung Sam Paik · 2021 · Diagnostics
Cancer stem cells and early stage basal-like breast cancer
Pang‐Kuo Lo, Benjamin Wolfson, Qun Yong Zhou · 2016 · World Journal of Obstetrics and Gynecology
Preoperative Therapy for Operable Breast Cancer
Yeşim Eralp · 2016 · Springer eBooks
AR/ERK co-targeting triggers ferroptosis via FOXC2 in triple-negative breast cancer
Yuhan Zhao, Chi Xu, Yiqiu Liu, Ye Zhu, Lingling Fan, Fangyan Gao, Xiaojie Liang, Yaqin Shi, Yongbin Chen, Xiaoxiang Guan · 2025 · Science China Life Sciences
Inhibition of UCH-L1 enhances immunotherapy efficacy in triple-negative breast cancer by stabilizing PD-L1
Linhao He, Jiaying He, Ting Jiang, Rong Gong, Xiaoya Wan, Mingwu Duan, Zonglin Chen, Yan Cheng · 2025 · European Journal of Pharmacology
Implementation of a High-Accuracy Targeted Gene Expression Panel for Clinical Care
Aileen Y. Alontaga, Pedro Cano, Hilal Özakıncı, John Puskas, Paul A. Stewart, Eric A. Welsh, Sean Yoder, James Kevin Hicks, Andreas Nicholas Saltos, Aaron Bossler et al. · 2024 · Journal of Molecular Diagnostics